Viatris Inc. Announces Third‑Quarter 2026 Results Date and UBS Adjusts Target Price
Viatris Inc. (Nasdaq: VTRS), a global pharmaceutical company, confirmed that it will report its third‑quarter 2026 financial results on Thursday, November 5, 2026. The company will host a conference call and a live webcast at 8:30 a.m. ET, which investors and the public may access through investor.viatris.com or by telephone. A recording of the webcast will be made available on the website following the live event.
In related market commentary, UBS has increased its price target for Viatris shares in light of positive developments concerning the company’s pipeline drug Cenerimod. The upgrade reflects optimism about the clinical and commercial prospects of the molecule, which is expected to address unmet needs in autoimmune disease treatment.
Viatris maintains a broad portfolio that spans generics, value‑added medicines, established brands, and innovative therapies. The company’s market capitalization is approximately $20.22 billion, and its 52‑week trading range extended from a low of $9.69 to a high of $18.43 in the previous year. Despite a negative price‑earnings ratio of –49.56, the firm’s earnings outlook is closely monitored by analysts following the upcoming quarterly report.
